Signing Ceremony of Strategic Cooperation between State Drug Administration and Peking University and Opening Ceremony of National Institute

At 9:00 on September 24, the signing ceremony of the strategic cooperation between State Drug Administration and Peking University and the inauguration ceremony of the National Institute of Pharmaceutical and Medical Devices Supervision and Regulation of Peking University were held in the 209 Lecture Hall of Yifu Teaching Building of the Ministry of Medicine.

Li Li, Secretary of the Party Group of the State Drug Administration, and Jiao Hong, Director of the State Drug Administration, Hao Ping, President of Peking University, Zhan Qimin, Executive Vice President of Peking University, Director of the Faculty of Medicine, and Academician of the Chinese Academy of Engineering, and Liu Yucun, Executive Deputy Secretary of Peking University, and Secretary of the CPC Committee of the Faculty of Medicine attended the event. The ceremony was presided over by Xiao Yuan, deputy director of the Faculty of Medicine.

"This is both an important initiative of the State Drug Administration to promote the implementation of China's drug regulatory science action plan, and one of the important means to actively promote the modernization of China's drug regulatory system and regulatory capacity." Jiao Hong introduced the unremitting efforts made by the State Drug Administration in recent years to firmly guard the bottom line of drug safety and promote the high-quality development of the pharmaceutical industry by strengthening the construction of the regulatory and standard system, deepening the reform of the review and approval system, carrying out extensive regulatory scientific research, and implementing the whole life cycle regulation.

Over the years, Peking University and the State Drug Administration (SDA) have carried out extensive cooperation, explored pragmatic and effective ways of cooperation, achieved fruitful and solid results, and laid a foundation for cooperation based on sincerity and mutual trust. Jiao Hong recounted the story behind the signing of the contract, saying that in the future, the two sides will rely on the co-construction of Peking University's National Institute of Pharmaceutical and Medical Devices Regulatory Science to further promote China's pharmaceutical regulatory science action plan, and carry out pragmatic cooperation in various fields such as research on drug policies and regulations, reform of the review and approval system, regulation of the whole life cycle of drugs, transformation of pharmaceutical scientific research results, and construction of a professional human resources team, etc., and uphold the principle of "people first, life first". Adhering to the concept of "people first, life first", Peking University will vigorously carry forward the great anti-epidemic spirit and make positive contributions to the construction of a healthy China.

Zhan Qimin introduced the contributions made by Peking University to the development of national healthcare under the guidance of the strategy of Healthy China, the strategy of Education for a Stronger Nation, and the strategy of Innovation Drive. Mr. Zhan said that Peking University will give full play to its solid educational, talent, academic and research resource advantages, and organically combine them with the practical experience of the State Drug Administration (SDA) to build the "Peking University National Institute of Pharmaceutical and Medical Devices Supervision and Regulation", to carry out in-depth research on the laws of the life cycle of pharmaceuticals and medical devices, and to provide a platform for the development of the pharmaceutical and medical devices supervision and regulation industry at home and abroad. It will build a platform of continuing education for professional training, communication and skill improvement for domestic and foreign personnel engaged in the regulation of drugs and medical devices; deepen the combination of medicine, research and enterprise, promote the transformation of research results, and increase the contribution rate of institutions of higher learning to the transformation and upgrading of the industry; and realize the effective linkage of medicine, medical care and medical insurance based on technology and science, and accelerate the effective transformation and implementation of new technologies, standards and methods for scientific regulation. Effective transformation and implementation. At the same time, it will further strengthen the close integration of scientific research and clinical trials, better play the role of demonstration and leadership of the National Clinical Medical Center, and build a first-class clinical drug research center.

Zhan Qimin hopes that in the future, the two sides will, with a sincere attitude, a spirit of practical work and solid actions, fully implement the requirements of General Secretary Xi Jinping's series of instructions on drug safety, such as the "four most stringent" instructions, and turn the content of the strategic cooperation framework agreement into an actionable and implementable project, so as to build a scientific system of drug and medical device supervision with Chinese characteristics, and promote the development of a new drug and medical device regulatory system with Chinese characteristics. The framework agreement will turn one item in the strategic cooperation agreement into an operational and implementable project, build a scientific system of drug and medical device regulation with Chinese characteristics, promote the development of innovative methods and technologies of regulatory science in China, and promote China's drug and medical device industry and regulatory level among the world's advanced ranks.

Jiao Hong, Zhan Qimin on behalf of the State Drug Administration and Peking University signed the "State Drug Administration - Peking University Strategic Cooperation Framework Agreement" "State Drug Administration and Peking University cooperation to build" Peking University National Institute of Drugs and Medical Devices Regulatory Science "agreement.

According to the agreement, the State Drug Administration and Peking University will focus on the "Healthy China" development strategy, make concerted efforts, all-round, multi-field, multi-channel co-construction of Peking University National Institute of Drugs and Medical Devices Supervision and Research.

The signing of this contract is a new starting point for the two sides to work together and seek common development. In the future, the two sides will share resources, complement each other's strengths, and continue to deepen the strategic cooperation between the two sides, and work together to seek common development.

Leaders from the relevant departments and bureaus of the State Drug Administration, directly under the unit, Peking University, Peking University Medical Department, relevant functional department heads, relevant department heads, hospital representatives, faculty and student representatives and other representatives to participate in this activity.

After the ceremony, the guests and their entourage came to the exhibition hall on the first floor of Shaw Teaching Building, visited the exhibition of the Centennial History of Peking University Medicine and the State Key Laboratory of Natural and Biomimetic Drugs, and learned about the brilliant history of Peking University Medicine and the internationally advanced public instrument platform of the laboratory; they came to the exhibition hall on the first floor of Science and Innovation Building, visited the exhibition of the "epidemic" of Peking University Medicine's medical team in Hubei He also came to the exhibition hall on the first floor of the Science and Innovation Building, visited the exhibition of "Epidemic" of the medical team of Peking University, listened to the heroic and touching story of the largest medical team of Peking University, understood the transformation of scientific and technological achievements and innovation and entrepreneurship of Peking University, and listened to the results of the existing cooperation between the two sides and the conception of further cooperation.